The TEG product line, which includes equipment, software and consumables, has been marketed successfully for over seven years. The TEG system is a proven technology backed by scores of scientific papers and reported data. Haemoscope has shown that by using the TEG system, on average, hospitals can reduce their need for blood transfusions by 20% or more annually.
Brad Nutter, Haemonetics’ president and CEO, said: “This is a strategic acquisition that strengthens our vision of being a global leader in blood management solutions for our customers. Haemoscope expands Haemonetics’ product portfolio by providing clinicians with a diagnostic tool to optimize blood management practice. The acquisition fits well with our recent Infonale acquisition, enabling Haemonetics to deliver a more complete blood management solution to the hospital market.”
The acquisition is expected to close within the next several weeks.